Alzheimer's disease (AD) is a neurodegenerative disease that leads to cognitive impairment and, ultimately, death. AD is the primary cause of dementia. In 2010, the worldwide prevalence of dementia was 35.6 million and this number is predicted to triple by 2050.
1 Currently, this disease can only be definitively diagnosed post mortem through the severity of 2 hallmarks: amyloid plaques (composed of misfolded amyloid-β protein) and neurofibrillary tangles (composed of tau protein), both of which begin to accumulate in the brain before symptoms of cognitive impairment.
2 Detection of amyloid, tau, and neurodegeneration in the brain is recommended for detecting changes associated with the AD disease process in clinical trials of novel treatments.
3 Confirmation of amyloid in the brain is currently achieved using positron emission tomography (PET) scans
4 or analyzing the cerebral spinal fluid.
5 However, both methods are invasive: PET scans use a radiative isotope injection,
4 and a cerebral spinal fluid test requires extraction of fluid from the patient's spine.
5 Currently, there is no effective cure for AD. However, it has been suggested that earlier detection of brain amyloid in prodromal disease could enable more successful treatment before damage from amyloid and tau accummulates.
6 Furthermore, the amyloid, tau, and neurodegeneration framework allows for the incorporation of other biomarkers of amyloid in the brain.
5 Therefore, it is important to develop a noninvasive method to detect amyloid in association with AD before AD diagnosis. Potential peripheral biomarkers of amyloid in the brain include detection of amyloid in the retina.
7